Mark Enyedy
Director/Board Member at ERGOMED
Mark Enyedy active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ERGOMED | Director/Board Member | 2021-06-09 | - |
| Independent Dir/Board Member | 2021-06-09 | - | |
| BIOMARIN PHARMACEUTICAL INC. | Director/Board Member | 2023-12-26 | - |
| Independent Dir/Board Member | 2023-12-26 | - | |
| American Cancer Society New England Division, Inc. | Director/Board Member | - | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - | - |
Career history of Mark Enyedy
Former positions of Mark Enyedy
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOGEN, INC. | Director/Board Member | 2016-05-15 | 2024-02-11 |
| Chief Executive Officer | 2016-05-15 | 2024-02-11 | |
| President | 2016-05-15 | 2024-02-11 | |
| LOGICBIO THERAPEUTICS, INC. | Director/Board Member | 2020-03-16 | 2022-11-15 |
| Independent Dir/Board Member | 2020-03-16 | 2022-11-15 | |
| AKEBIA THERAPEUTICS, INC. | Director/Board Member | 2018-12-11 | 2021-06-01 |
| Independent Dir/Board Member | 2018-12-11 | 2021-06-01 | |
| KERYX BIOPHARMACEUTICALS | Director/Board Member | 2017-09-12 | 2018-12-11 |
| Independent Dir/Board Member | 2017-09-12 | 2018-12-11 | |
| FATE THERAPEUTICS, INC. | Director/Board Member | 2012-06-30 | 2018-05-01 |
| Independent Dir/Board Member | 2012-06-30 | 2018-05-01 | |
| ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░ ░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Mark Enyedy
| Northeastern University | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Statistics
International
| United States | 14 |
| Ireland | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 10 |
| Independent Dir/Board Member | 6 |
| Corporate Officer/Principal | 3 |
Sectoral
| Health Technology | 10 |
| Commercial Services | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| ERGOMED | Commercial Services |
| Private companies | 8 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
| American Cancer Society New England Division, Inc. | |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Mark Enyedy
- Experience
